79 completed, 7 terminated, 6 recruiting, 5 unknown. 30 Phase 2, 22 Phase 3, 20 Phase 1, 18 Phase 4, 11 Not applicable.
Follow Dutasteride: new trials by email Literature Review of Dutasteride trials Research Report on Dutasteride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Long-term Dutasteride Use on Perioperative Outcomes of HoLEP Dutasteride, Holmium Laser Enucleation of the Prostate (HoLEP) - Prostatic Hyperplasia, Benign | Recruiting | Ankara City Hospital Bilkent | 1000 | 2026-04-01 | 2026-04-06 | |
| Evaluation of Topical Dutasteride as a Potential New Therapy for Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel) topical dutasteride - Acne Vulgaris | Not applicable | Not yet recruiting | Assiut University | 50 | 2026-04-01 | 2026-02-19 |
| Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer Dutasteride (0.5mg) - Bladder Cancer | Phase 2 | Recruiting | Paul Toren | 95 | 2026-03-25 | 2026-03-30 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia CKD-843 dose#1, CKD-843 dose#2, Placebo of CKD-843 dose - Androgenetic Alopecia | Phase 3 | Recruiting | Chong Kun Dang Pharmaceutical | 288 | 2025-04-08 | 2026-09-03 |
| Effetivity of Dutasteride and Aloe Vera Extract Combination on Angiogenesis and Obstruction on Benign Prostatic Hyperplasia Aloevera + dutasteride, Dutasteride (0.5mg) - BPH (Benign Prostatic Hyperplasia) | Phase 1 | Recruiting | Universitas Diponegoro | 84 | 2023-07-01 | 2025-07-15 |
| Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP) Dutasteride, Abiraterone - Prostate Cancer | Phase 2 | Withdrawn | Masonic Cancer Center, University of Minnesota | 2023-02-01 | 2023-02-27 | |
| Prostate Medication, Metabolism and Gut Microbiota Prostate hyperplasia medication, LhRH-antagonist - Prostatic Hyperplasia, Prostate Cancer | Phase 4 | Recruiting | Turku University Hospital | 100 | 2022-12-01 | 2023-08-21 |
| Clinical Trial of Safety and Efficacy of Daily Application of Topical Dutasteride in Men With Androgenic Alopecia. Dutasteride, Placebo - Male Androgenetic Alopecia | Phase 2 | Completed | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | 45 | 2022-09-29 | 2024-09-19 |
| Phase II Dutasteride in Combination With CAB vs CAB in SDC Goserelin 10.8 mg, Bicalutamide 50 mg, Dutasteride 0.5 mg - Salivary Duct Carcinoma | Phase 2 | Recruiting | Radboud University Medical Center | 26 | 2022-09-27 | 2025-06-04 |
| Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia DKF-313, Dutasteride, Tadalafil - Benign Prostatic Hyperplasia | Phase 3 | Completed | Dongkook Pharmaceutical Co., Ltd. | 667 | 2021-07-27 | 2023-09-21 |
| Study of PCUR-101 in Combination With ADT in Patients With mCRPC PCUR-101, Dutasteride 0.5 mg, Abiraterone and Prednisone - Prostate Cancer | Phase 1 | Terminated | Pellficure Pharmaceuticals, Inc | 7 | 2021-03-30 | 2024-04-10 |
| EAT-DUTA AndroCoV Trial Dutasteride 0.5 mg, Azithromycin, Nitazoxanide - Covid19 | Phase 2 / Phase 3 | Completed | Corpometria Institute | 138 | 2020-06-30 | 2021-01-28 |
| Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy Dutasteride Capsules, Placebo Capsules - Alcohol Use Disorder | Phase 2 / Phase 3 | Completed | UConn Health | 180 | 2019-10-15 | 2025-05-09 |
| ITT-5 Mechanisms of Spermatogenesis in Man Testosterone 1% Gel, Acyline, Dutasteride - Gonadotropin Deficiency | Phase 2 | Withdrawn | University of Washington | 2019-06-01 | 2019-12-18 | |
| Role of Dutasteride in Treatment of Chronic Prostatitis Dutasteride 0.5 mg, Placebo - Dutasteride, Category IIIB Chronic Prostatitis | Phase 2 / Phase 3 | Completed | Ain Shams University | 50 | 2019-01-01 | 2021-02-16 |
| Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil Dutasteride 0.5 mg, Tadalafil 5 mg, YY-201 - Benign Prostatic Hyperplasia | Phase 1 | Completed | Yuyu Pharma, Inc. | 36 | 2017-03-27 | 2017-11-24 |
| A Study to Investigate the Pharmacokinetic Drug Interactions Between Dutasteride and Tadalafil in Healthy Male Subjects Tadalafil, Dutasteride - Benign Prostate Hyperplasia | Phase 1 | Completed | Yuyu Pharma, Inc. | 28 | 2016-05-01 | 2017-04-04 |
| The Efficacy of Nano-water in Combination With Tamsulosin- Dutasteride for Lower Urinary Tract Symptoms Nano-water, Tamsulosin Dutasteride, Regular water, tamsulosin, Dutasteride - Lower Urinary Tract Symptoms | Not applicable | Completed | ALI KAMAL M. SAMI | 210 | 2016-02-16 | 2024-11-06 |
| Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects FDC capsule of dutasteride and tamsulosin, Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet - Prostatic Hyperplasia | Phase 1 | Completed | GlaxoSmithKline | 56 | 2015-07-30 | 2018-06-19 |
| Safety and Pharmacokinetic Characteristics of DKF-313 DKF-313, AVODART, CIALIS - Benign Prostate Hyperplasia, Healthy | Phase 1 | Completed | Dongkook Pharmaceutical Co., Ltd. | 54 | 2015-01-01 | 2021-07-06 |
Showing 20 of 104. Sign in to see all of them.
Prostatic Hyperplasia (45) · Prostatic Neoplasms (31) · Alopecia (7) · Alcoholism (5) · Hypogonadism (5) · Neoplasms (4) · Lower Urinary Tract Symptoms (3) · Alcohol-Related Disorders (2) · Transsexualism (2) · Acne Vulgaris (1) · Bulbo-Spinal Atrophy, X-Linked (1) · COVID-19 (1) · Depression (1) · Erectile Dysfunction (1) · Hyperplasia (1)
GlaxoSmithKline (34) · University of Washington (7) · UConn Health (5) · Dongkook Pharmaceutical Co., Ltd. (3) · CHU de Quebec-Universite Laval (2) · Unita Complessa di Ostetricia e Ginecologia (2) · Yuyu Pharma, Inc. (2) · ALI KAMAL M. SAMI (1) · Ain Shams University (1) · Ankara City Hospital Bilkent (1) · Assiut University (1) · Bay State Clinical Trials, Inc. (1) · Beth Israel Deaconess Medical Center (1) · Canadian Urology Research Consortium (1) · Chong Kun Dang Pharmaceutical (1)
United States (45) · Canada (13) · South Korea (11) · Netherlands (8) · United Kingdom (8) · Australia (7) · Spain (7) · France (6) · Germany (6) · Finland (5) · Greece (5) · Japan (5) · Russia (5) · Taiwan (5) · Argentina (4)
Jonathan Covault, MD, PhD (3) · Laurence Klotz, MD (2) · William J Bremner, MD, PhD (2) · Abraham Morgentaler, MD (1) · Al Barqawi, MD (1) · Ali K M. Sami (1) · Alvin M Matsumoto, MD (1) · Andre-Guy Martin, MD (1) · Andy Goren, MD (1) · Carlos G. Wambier, MD, Ph.D. (1) · Charles Ryan, MD (1) · Cheng Cheng Wang, M.D Ph.D (1) · Choung-Soo Kim, M.D.,Ph.D (1)
PMID 18046048, PMID 18077826, PMID 19091347, PMID 19846582, PMID 21216197, PMID 21575967, PMID 22017520, PMID 22396515, PMID 22998915, PMID 23176897, PMID 23348398, PMID 23533230, PMID 23541458, PMID 23587564, PMID 23851165, PMID 24323034, PMID 24876969, PMID 25091040, PMID 25320358, PMID 25988518, PMID 26165588, PMID 26184556, PMID 26893187, PMID 27378134, PMID 27536459, PMID 27683182, PMID 28396999, PMID 28800206, PMID 29044968, PMID 29161905, PMID 29280355, PMID 30214036, PMID 31801152, PMID 32134978, PMID 32167484, PMID 32856605, PMID 36570649, PMID 38684046
K23HD045386 (2), P60AA003510 (2), R01AA015606 (2), P50AA027055 (1), R01CA155301 (1), R01HD043348 (1), U54HD012629 (1), U54HD042454 (1)